Delving into the Latest Updates on Modimelanotide with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

Ac-(Lys)6-alphaMSH

+ [1]

Target

MC1R x MC3R x MC4R x MC5R

Mechanism

MC1R agonists(Melanocortin receptor 1 agonists), MC3R agonists(Melanocortin receptor 3 agonists), MC4R agonists(Melanocortin receptor 4 agonists)

+ [1]

Therapeutic Areas

Cardiovascular DiseasesUrogenital DiseasesRespiratory Diseases+ [1]

Active Indication-

Inactive Indication

Acute Kidney InjuryAortic AneurysmCardiovascular Diseases+ [7]

Originator Organization

Zealand Pharma A/S

Active Organization-

Inactive Organization

Action Pharma A/S

AbbVie, Inc.

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Structure

Molecular FormulaC113H181N33O25S

InChIKeyWHRVKPBBRZHWTN-ZHHKRVSMSA-N

CAS Registry926277-68-1

Gene Sequence

Sequence Code 14547742

Source: *****

Acute kidney injury (AKI) is a significant source of morbidity and mortality in pediatric patients, affecting more than one quarter of critically ill children. Despite significant need, there are no targeted therapies to reliably prevent or treat AKI. Recent advances in our understanding of renal injury and repair signaling pathways have enabled the development of several targeted pharmaceuticals. Here we review emerging pharmacotherapies for AKI that are currently in clinical trials. Categorized by their general mechanism of action, the therapies discussed include anti-inflammatory agents (recAP, AB103, ABT-719), antioxidants (iron chelators, heme arginate), vasodilators (levosimendan), apoptosis inhibitors (QPI-1002), and repair agents (THR-184, BB-3, mesenchymal stem cells).

01 Feb 2017·Expert Opinion on Investigational DrugsQ2 · MEDICINE

Recent early clinical drug development for acute kidney injury

Q2 · MEDICINE

Review

Author: Ross, James A ; Hughes, Jeremy ; Gallagher, Kevin M. ; Harrison, Ewen M ; O’neill, Stephen ; Wigmore, Stephen J

INTRODUCTIONDespite significant need and historical trials, there are no effective drugs in use for the prevention or treatment of acute kidney injury (AKI). There are several promising agents in early clinical development for AKI and two trials have recently been terminated. There are also exciting new findings in pre-clinical AKI research. There is a need to take stock of current progress in the field to guide future drug development for AKI. Areas covered: The main clinical trial registries, PubMed and pharmaceutical company website searches were used to extract the most recent clinical trials for sterile, transplant and sepsis-associated AKI. We summarise the development of the agents recently in clinical trial, update on their trial progress, consider reasons for failed efficacy of two agents, and discuss new paradigms in pre-clinical targets for AKI. Agents covered include- QPI-1002, THR-184, BB-3, heme arginate, human recombinant alkaline phosphatase (recAP), ciclosporin A, AB103, levosimendan, AC607 and ABT-719. Expert opinion: Due to the heterogenous nature of AKI, agents with the widest pleiotropic effects on multiple pathophysiological pathways are likely to be most effective. Linking preclinical models to clinical indication and improving AKI definition and diagnosis are key areas for improvement in future clinical trials.

01 Nov 2015·Antimicrobial Agents and ChemotherapyQ2 · MEDICINE

Protective Effect of Qnr on Agents Other than Quinolones That Target DNA Gyrase

Q2 · MEDICINE

Article

Author: Corcoran, Marian A. ; Hooper, David C. ; Jacoby, George A.

ABSTRACTQnr is a plasmid-encoded and chromosomally determined protein that protects DNA gyrase and topoisomerase IV from inhibition by quinolones. Despite its prevalence worldwide and existence prior to the discovery of quinolones, its native function is not known. Other synthetic compounds and natural products also target bacterial topoisomerases. A number were studied as molecular probes to gain insight into how Qnr acts. Qnr blocked inhibition by synthetic compounds with somewhat quinolone-like structure that target the GyrA subunit, such as the 2-pyridone ABT-719, the quinazoline-2,4-dione PD 0305970, and the spiropyrimidinetrione pyrazinyl-alkynyl-tetrahydroquinoline (PAT), indicating that Qnr is not strictly quinolone specific, but Qnr did not protect against GyrA-targeting simocyclinone D8 despite evidence that both simocyclinone D8 and Qnr affect DNA binding to gyrase. Qnr did not affect the activity of tricyclic pyrimidoindole or pyrazolopyridones, synthetic inhibitors of the GyrB subunit, or nonsynthetic GyrB inhibitors, such as coumermycin A1, novobiocin, gyramide A, or microcin B17.Thus, in this set of compounds the protective activity of Qnr was confined to those that, like quinolones, trap gyrase on DNA in cleaved complexes.

100 Deals associated with Modimelanotide

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Modimelanotide	-	DB15314

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cardiovascular Diseases	Phase 2	US	AbbVie, Inc.	01 May 2013
Cardiovascular Diseases	Phase 2	DK	AbbVie, Inc.	01 May 2013
Aortic Aneurysm	Phase 2	DK	Action Pharma A/S	01 Oct 2010
Coronary Artery Disease	Phase 2	DK	Action Pharma A/S	01 Oct 2010
Heart Valve Diseases	Phase 2	DK	Action Pharma A/S	01 Oct 2010
Kidney Diseases	Phase 2	DK	Action Pharma A/S	01 Oct 2010
Acute Kidney Injury	Phase 2	US	Action Pharma A/S	01 Mar 2008
Myocardial Infarction	Phase 2	-	Action Pharma A/S	-
Reperfusion Injury	Phase 2	-	Action Pharma A/S	-
Respiratory Distress Syndrome, Adult	Phase 2	DK	Action Pharma A/S	-